Nuclear medicine communications
Predicting hematologic toxicity of lutetium-177 prostate-specific membrane antigen therapy in metastatic castration-resistant prostate cancer using pretreatment gallium-68 prostate-specific membrane antigen positron emission tomography imaging: preliminary data in Asian patients.
Yu-Yi Huang, Kuo-Cheng Huang, Pei-Ing Lee
Published: 202510.1097/MNM.0000000000002086
Abstract
BACKGROUND: Lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) therapy is an emerging treatment for metastatic castration-resistant prostate cancer (mCRPC), but there is limited evidence on whether imaging can predict treatment-related t…
Preview only. Read the full abstract at the source